Skip to Main Content

Paper Details

Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging role.
Ther Adv Med Oncol
30
2022
Author NameAffiliation
Aditya BardiaMassachusetts General Hospital Cancer Center, Harvard Medical School
  • 1 - 1

Datasets

Release 1.2